Biomarkers in sarcoidosis

References

• Strimbu K, Tavel JA. What are biomarkers? Curr Opin HIV AIDS. 2010;5(6):463–466.
   PubMed Web of Science ®Google Scholar
• Biomarkers Definition Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69(3):89–95.
   PubMed Web of Science ®Google Scholar
• Hunninghake GW, Costabel U, Ando M, et al. ATS/ERS/WASOG statement on sarcoidosis. American thoracic society/European respiratory society/World association of sarcoidosis and other granulomatous disorders. Sarcoidosis Vasc Diffuse Lung Dis. 1999;16(2):149–173.
   PubMed Web of Science ®Google Scholar
• Judson MA. Advances in the diagnosis and treatment of sarcoidosis. F1000Prime Rep. 2014;6:89.
   PubMedGoogle Scholar
• Baughman RP, Nagai S, Balter M, et al. Defining the clinical outcome status (COS) in sarcoidosis: results of WASOG task force. Sarcoidosis Vasc Diffuse Lung Dis. 2011;28(1):56–64.
   PubMed Web of Science ®Google Scholar
• Baydur A, Alsalek M, Louie SG, et al. Respiratory muscle strength, lung function, and dyspnea in patients with sarcoidosis. Chest. 2001;120(1):102–108.
   PubMed Web of Science ®Google Scholar
• Judson MA. Quality of life assessment in sarcoidosis. Clin Chest Med. 2015;36(4):739–750.
   PubMed Web of Science ®Google Scholar
• Jameson JL, Longo DL. Precision medicine–personalized, problematic, and promising. N Engl J Med. 2015;372(23):2229–2234.
   PubMed Web of Science ®Google Scholar
• Ryan JW, Smith U, Niemeyer RS. Angiotensin I: metabolism by plasma membrane of lung. Science. 1972;176(4030):64–66.
   PubMed Web of Science ®Google Scholar
• Coates D. The angiotensin converting enzyme (ACE). Int J Biochem Cell Biol. 2003;35(6):769–773.
   PubMed Web of Science ®Google Scholar
• Sheffield EA. Pathology of sarcoidosis. Clin Chest Med. 1997;18(4):741–754.
   PubMed Web of Science ®Google Scholar
• Lynch JP 3rd, Kazerooni EA, Gay SE. Pulmonary sarcoidosis. Clin Chest Med. 1997;18(4):755–785.
   PubMed Web of Science ®Google Scholar
• Rohatgi PK, Ryan JW. Simple radioassay for measuring serum activity of angiotensin-converting enzyme in sarcoidosis. Chest. 1980;78(1):69–76.
   PubMed Web of Science ®Google Scholar
• Studdy P, Bird R, James DG. Serum angiotensin-converting enzyme (SACE) in sarcoidosis and other granulomatous disorders. Lancet. 1978;2(8104–5):1331–1334.
   PubMed Web of Science ®Google Scholar
• Lavaud F, Nou JM, Hinnrasky J, et al. Assay of angiotensin converting enzyme (ACE) in thoracic forms of sarcoidosis and other pulmonary diseases. Nouv Presse Med. 1979;8(45):3755.
   PubMedGoogle Scholar
• Nosal A, Schleissner LA, Mishkin FS, et al. Angiotensin-I-converting enzyme and gallium scan in noninvasive evaluation of sarcoidosis. Ann Intern Med. 1979;90(3):328–331.
   PubMed Web of Science ®Google Scholar
• Lieberman J. The specificity and nature of serum-angiotensin-converting enzyme (serum ACE) elevations in sarcoidosis. Ann N Y Acad Sci. 1976;278:488–497.
   PubMed Web of Science ®Google Scholar
• Lieberman J, Schleissner LA, Nosal A, et al. Clinical correlations of serum angiotensin-converting enzyme (ACE) in sarcoidosis. A longitudinal study of serum ACE, 67gallium scans, chest roentgenograms, and pulmonary function. Chest. 1983;84(5):522–528.
   PubMed Web of Science ®Google Scholar
• Ashutosh K, Keighley JF. Diagnostic value of serum angiotensin converting enzyme activity in lung diseases. Thorax. 1976;31(5):552–557.
   PubMed Web of Science ®Google Scholar
• Rohrbach MS, Deremee RA. Serum angiotensin converting enzyme activity in sarcoidosis as measured by a simple radiochemical assay. Am Rev Respir Dis. 1979;119(5):761–767.
   PubMed Web of Science ®Google Scholar
• Klech H, Kohn H, Kummer F, et al. Assessment of activity in sarcoidosis. Sensitivity and specificity of 67Gallium scintigraphy, serum ACE levels, chest roentgenography, and blood lymphocyte subpopulations. Chest. 1982;82(6):732–738.
   PubMed Web of Science ®Google Scholar
• Krasowski MD, Savage J, Ehlers A, et al. Ordering of the serum angiotensin-converting enzyme test in patients receiving angiotensin-converting enzyme inhibitor therapy: an avoidable but common error. Chest. 2015;148(6):1447–1453.
   PubMed Web of Science ®Google Scholar
• Lieberman J, Rea TH. Serum angiotensin-converting enzyme in leprosy and coccidioidomycosis. Ann Intern Med. 1977;87(4):423–425.
   PubMedGoogle Scholar
• Ryder KW, Jay SJ, Kiblawi SO, et al. Serum angiotensin converting enzyme activity in patients with histoplasmosis. JAMA. 1983;249(14):1888–1889.
   PubMed Web of Science ®Google Scholar
• Brice EA, Friedlander W, Bateman ED, et al. Serum angiotensin-converting enzyme activity, concentration, and specific activity in granulomatous interstitial lung disease, tuberculosis, and COPD. Chest. 1995;107(3):706–710.
   PubMed Web of Science ®Google Scholar
• Lieberman J, Beutler E. Elevation of serum angiotensin-converting enzyme in Gaucher’s disease. N Engl J Med. 1976;294(26):1442–1444.
   PubMed Web of Science ®Google Scholar
• Bunting PS, Szalai JP, Katic M. Diagnostic aspects of angiotensin converting enzyme in pulmonary sarcoidosis. Clin Biochem. 1987;20(3):213–219.
   PubMed Web of Science ®Google Scholar
• Lieberman J, Nosal A, Schlessner A, et al. Serum angiotensin-converting enzyme for diagnosis and therapeutic evaluation of sarcoidosis. Am Rev Respir Dis. 1979;120(2):329–335.
   PubMed Web of Science ®Google Scholar
• Joseph FG, Scolding NJ. Neurosarcoidosis: a study of 30 new cases. J Neurol Neurosurg Psychiatry. 2009;80(3):297–304.
   PubMed Web of Science ®Google Scholar
• Khoury J, Wellik KE, Demaerschalk BM, et al. Cerebrospinal fluid angiotensin-converting enzyme for diagnosis of central nervous system sarcoidosis. Neurologist. 2009;15(2):108–111.
   PubMed Web of Science ®Google Scholar
• Sharma OP. Neurosarcoidosis: a personal perspective based on the study of 37 patients. Chest. 1997;112(1):220–228.
   PubMed Web of Science ®Google Scholar
• Dale JC, O’Brien JF. Determination of angiotensin-converting enzyme levels in cerebrospinal fluid is not a useful test for the diagnosis of neurosarcoidosis. Mayo Clinic Proc. 1999;74(5):535.
   PubMed Web of Science ®Google Scholar
• Tahmoush AJ, Amir MS, Connor WW, et al. CSF-ACE activity in probable CNS neurosarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2002;19(3):191–197.
   PubMed Web of Science ®Google Scholar
• Pietinalho A, Furuya K, Yamaguchi E, et al. The angiotensin-converting enzyme DD gene is associated with poor prognosis in Finnish sarcoidosis patients. Eur Respir J. 1999;13(4):723–726.
   PubMed Web of Science ®Google Scholar
• Tomita H, Ina Y, Sugiura Y, et al. Polymorphism in the angiotensin-converting enzyme (ACE) gene and sarcoidosis. Am J Respir Crit Care Med. 1997;156(1):255–259.
   PubMed Web of Science ®Google Scholar
• Furuya K, Yamaguchi E, Itoh A, et al. Deletion polymorphism in the angiotensin I converting enzyme (ACE) gene as a genetic risk factor for sarcoidosis. Thorax. 1996;51(8):777–780.
   PubMed Web of Science ®Google Scholar
• Floe A, Hoffmann HJ, Nissen PH, et al. Genotyping increases the yield of angiotensin-converting enzyme in sarcoidosis–a systematic review. Dan Med J. 2014;61(5):A4815.
   PubMed Web of Science ®Google Scholar
• Stokes GS, Monaghan JC, Schrader AP, et al. Influence of angiotensin converting enzyme (ACE) genotype on interpretation of diagnostic tests for serum ACE activity. Aust N Z J Med. 1999;29(3):315–318.
   PubMedGoogle Scholar
• De Smet D, Martens GA, Berghe BV, et al. Use of likelihood ratios improves interpretation of laboratory testing for pulmonary sarcoidosis. Am J Clin Pathol. 2010;134(6):939–947.
   PubMed Web of Science ®Google Scholar
• Takada Y, Hiwada K, Akutsu H, et al. The immunocytochemical detection of angiotensin-converting enzyme in alveolar macrophages from patients with sarcoidosis. Lung. 1984;162(6):317–323.
   PubMed Web of Science ®Google Scholar
• Silverstein E, Pertschuk LP, Friedland J. Immunofluorescent localization of angiotensin converting enzyme in epithelioid and giant cells of sarcoidosis granulomas. Proc Natl Acad Sci U S A. 1979;76(12):6646–6648.
   PubMed Web of Science ®Google Scholar
• Okabe T, Suzuki A, Ishikawa H, et al. Cells originating from sarcoid granulomas in vitro. Am Rev Respir Dis. 1981;124(5):608–612.
   PubMed Web of Science ®Google Scholar
• Gilbert S, Steinbrech DS, Landas SK, et al. Amounts of angiotensin-converting enzyme mRNA reflect the burden of granulomas in granulomatous lung disease. Am Rev Respir Dis. 1993;148(2):483–486.
   PubMed Web of Science ®Google Scholar
• Selroos OB. Biochemical markers in sarcoidosis. Crit Rev Clin Lab Sci. 1986;24(3):185–216.
   PubMed Web of Science ®Google Scholar
• Selroos OB. Value of biochemical markers in serum for determination of disease activity in sarcoidosis. Sarcoidosis. 1984;1(1):45–49.
   PubMedGoogle Scholar
• DeRemee RA, Rohrbach MS. Serum angiotensin-converting enzyme activity in evaluating the clinical course of sarcoidosis. Ann Intern Med. 1980;92(3):361–365.
   PubMed Web of Science ®Google Scholar
• Cohen RD, Bunting PS, Meindok HO, et al. Does serum angiotensin converting enzyme reflect intensity of alveolitis in sarcoidosis? Thorax. 1985;40(7):497–500.
   PubMed Web of Science ®Google Scholar
• Beaumont D, Herry JY, Sapene M, et al. Gallium-67 in the evaluation of sarcoidosis: correlations with serum angiotensin-converting enzyme and bronchoalveolar lavage. Thorax. 1982;37(1):11–18.
   PubMed Web of Science ®Google Scholar
• Finkel R, Teirstein AS, Levine R, et al. Pulmonary function tests, serum angiotensin-converting enzyme levels, and clinical findings as prognostic indicators in sarcoidosis. Ann N Y Acad Sci. 1986;465:665–671.
   PubMed Web of Science ®Google Scholar
• Rust M, Bergmann L, Kuhn T, et al. Prognostic value of chest radiograph, serum-angiotensin-converting enzyme and T helper cell count in blood and in bronchoalveolar lavage of patients with pulmonary sarcoidosis. Respir: Int Rev Thorac Dis. 1985;48(3):231–236.
   Google Scholar
• Baughman RP, Ploysongsang Y, Roberts RD, et al. Effects of sarcoid and steroids on angiotensin-converting enzyme. Am Rev Respir Dis. 1983;128(4):631–633.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Fernandez M, Bosken CH, et al. Comparison of gallium-67 scanning, bronchoalveolar lavage, and serum angiotensin-converting enzyme levels in pulmonary sarcoidosis. Predicting response to therapy. Am Rev Respir Dis. 1984;129(5):676–681.
   PubMed Web of Science ®Google Scholar
• Snider GL. Prediction of therapeutic response in steroid-treated pulmonary sarcoidosis. Am Rev Respir Dis. 1985;132(5):1139–1140.
   PubMed Web of Science ®Google Scholar
• Hollinger WM, Staton GW Jr., Fajman WA, et al. Prediction of therapeutic response in steroid-treated pulmonary sarcoidosis. Evaluation of clinical parameters, bronchoalveolar lavage, gallium-67 lung scanning, and serum angiotensin-converting enzyme levels. Am Rev Respir Dis. 1985;132(1):65–69.
   PubMed Web of Science ®Google Scholar
• Gronhagen-Riska C, Selroos O, Niemisto M. Angiotensin converting enzyme. V. Serum levels as monitors of disease activity in corticosteroid-treated sarcoidosis. Eur J Respir Dis. 1980;61(2):113–122.
   PubMedGoogle Scholar
• Mordelet-Dambrine MS, Stanislas-Leguern GM, Huchon GJ, et al. Elevation of the bronchoalveolar concentration of angiotensin I converting enzyme in sarcoidosis. Am Rev Respir Dis. 1982;126(3):472–475.
   PubMed Web of Science ®Google Scholar
• Specks U, Martin WJ 2nd, Rohrbach MS. Bronchoalveolar lavage fluid angiotensin-converting enzyme in interstitial lung diseases. Am Rev Respir Dis. 1990;141(1):117–123.
   PubMed Web of Science ®Google Scholar
• Hunninghake GW, Crystal RG. Pulmonary sarcoidosis: a disorder mediated by excess helper T-lymphocyte activity at sites of disease activity. N Engl J Med. 1981;305(8):429–434.
   PubMed Web of Science ®Google Scholar
• Saltini C, Spurzem JR, Lee JJ, et al. Spontaneous release of interleukin 2 by lung T lymphocytes in active pulmonary sarcoidosis is primarily from the Leu3+DR+ T cell subset. J Clin Invest. 1986;77(6):1962–1970.
   PubMed Web of Science ®Google Scholar
• Muller-Quernheim J. Sarcoidosis: immunopathogenetic concepts and their clinical application. Eur Respir J. 1998;12(3):716–738.
   PubMed Web of Science ®Google Scholar
• Semenzato G, Pizzolo G, Zambello R. The interleukin-2/interleukin-2 receptor system: structural, immunological, and clinical features. Int J Clin Lab Res. 1992;22(3):133–142.
   PubMedGoogle Scholar
• Keicho N, Kitamura K, Takaku F, et al. Serum concentration of soluble interleukin-2 receptor as a sensitive parameter of disease activity in sarcoidosis. Chest. 1990;98(5):1125–1129.
   PubMed Web of Science ®Google Scholar
• Bargagli E, Bianchi N, Margollicci M, et al. Chitotriosidase and soluble IL-2 receptor: comparison of two markers of sarcoidosis severity. Scand J Clin Lab Invest. 2008;68(6):479–483.
   PubMed Web of Science ®Google Scholar
• Grutters JC, Fellrath JM, Mulder L, et al. Serum soluble interleukin-2 receptor measurement in patients with sarcoidosis: a clinical evaluation. Chest. 2003;124(1):186–195.
   PubMed Web of Science ®Google Scholar
• Rothkrantz-Kos S, Van Dieijen-Visser MP, Mulder PG, et al. Potential usefulness of inflammatory markers to monitor respiratory functional impairment in sarcoidosis. Clin Chem. 2003;49(9):1510–1517.
   PubMed Web of Science ®Google Scholar
• Semenzato G, Foa R, Agostini C, et al. High serum levels of soluble interleukin 2 receptor in patients with B chronic lymphocytic leukemia. Blood. 1987;70(2):396–400.
   PubMed Web of Science ®Google Scholar
• Tung KS, Umland E, Matzner P, et al. Soluble serum interleukin 2 receptor levels in leprosy patients. Clin Exp Immunol. 1987;69(1):10–15.
   PubMed Web of Science ®Google Scholar
• Meliconi R, Lalli E, Borzi RM, et al. Idiopathic pulmonary fibrosis: can cell mediated immunity markers predict clinical outcome? Thorax. 1990;45(7):536–540.
   PubMed Web of Science ®Google Scholar
• Kloster BE, John PA, Miller LE, et al. Soluble interleukin 2 receptors are elevated in patients with AIDS or at risk of developing AIDS. Clin Immunol Immunopathol. 1987;45(3):440–446.
   PubMedGoogle Scholar
• Clements PJ, Peter JB, Agopian MS, et al. Elevated serum levels of soluble interleukin 2 receptor, interleukin 2 and neopterin in diffuse and limited scleroderma: effects of chlorambucil. J Rheumatol. 1990;17(7):908–910.
   PubMed Web of Science ®Google Scholar
• Brown AE, Rieder KT, Webster HK. Prolonged elevations of soluble interleukin-2 receptors in tuberculosis. Am Rev Respir Dis. 1989;139(4):1036–1038.
   PubMed Web of Science ®Google Scholar
• Lawrence EC, Brousseau KP, Berger MB, et al. Elevated concentrations of soluble interleukin-2 receptors in serum samples and bronchoalveolar lavage fluids in active sarcoidosis. Am Rev Respir Dis. 1988;137(4):759–764.
   PubMed Web of Science ®Google Scholar
• Ziegenhagen MW, Rothe ME, Schlaak M, et al. Bronchoalveolar and serological parameters reflecting the severity of sarcoidosis. Eur Respir J. 2003;21(3):407–413.
   PubMed Web of Science ®Google Scholar
• Ziegenhagen MW, Benner UK, Zissel G, et al. Sarcoidosis: TNF-alpha release from alveolar macrophages and serum level of sIL-2R are prognostic markers. Am J Respir Crit Care Med. 1997;156(5):1586–1592.
   PubMed Web of Science ®Google Scholar
• Van Eijk M, Van Roomen CP, Renkema GH, et al. Characterization of human phagocyte-derived chitotriosidase, a component of innate immunity. Int Immunol. 2005;17(11):1505–1512.
   PubMed Web of Science ®Google Scholar
• Michelakakis H, Dimitriou E, Labadaridis I. The expanding spectrum of disorders with elevated plasma chitotriosidase activity: an update. J Inherit Metab Dis. 2004;27(5):705–706.
   PubMed Web of Science ®Google Scholar
• Barone R, Simpore J, Malaguarnera L, et al. Plasma chitotriosidase activity in acute Plasmodium falciparum malaria. J Trop Pediatr. 2003;49(1):63–64.
   PubMed Web of Science ®Google Scholar
• Barone R, Simpore J, Malaguarnera L, et al. Plasma chitotriosidase activity in acute Plasmodium falciparum malaria. Clin Chim Acta. 2003;331(1–2):79–85.
   PubMed Web of Science ®Google Scholar
• Tercelj M, Salobir B, Simcic S, et al. Chitotriosidase activity in sarcoidosis and some other pulmonary diseases. Scand J Clin Lab Invest. 2009;69(5):575–578.
   PubMed Web of Science ®Google Scholar
• Bargagli E, Bennett D, Maggiorelli C, et al. Human chitotriosidase: a sensitive biomarker of sarcoidosis. J Clin Immunol. 2013;33(1):264–270.
   PubMed Web of Science ®Google Scholar
• Altarescu G, Rudensky B, Abrahamov A, et al. Plasma chitotriosidase activity in patients with beta-thalassemia. Am J Hematol. 2002;71(1):7–10.
   PubMed Web of Science ®Google Scholar
• Bargagli E, Margollicci M, Nikiforakis N, et al. Chitotriosidase activity in the serum of patients with sarcoidosis and pulmonary tuberculosis. Respir: Int Rev Thorac Dis. 2007;74(5):548–552.
   Google Scholar
• Harlander M, Maver A, Tercelj M, et al. Common chitotriosidase duplication gene polymorphism and clinical outcome status in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2015;32(3):194–199.
   PubMed Web of Science ®Google Scholar
• Bargagli E, Mazzi A, Rottoli P. Markers of inflammation in sarcoidosis: blood, urine, BAL, sputum, and exhaled gas. Clin Chest Med. 2008;29(3):445–458, viii.
   PubMed Web of Science ®Google Scholar
• Boot RG, Hollak CE, Verhoek M, et al. Plasma chitotriosidase and CCL18 as surrogate markers for granulomatous macrophages in sarcoidosis. Clin Chim Acta. 2010;411(1–2):31–36.
   PubMed Web of Science ®Google Scholar
• Grosso S, Margollicci MA, Bargagli E, et al. Serum levels of chitotriosidase as a marker of disease activity and clinical stage in sarcoidosis. Scand J Clin Lab Invest. 2004;64(1):57–62.
   PubMed Web of Science ®Google Scholar
• Bargagli E, Rottoli P. Serum chitotriosidase activity in sarcoidosis patients. Rheumatol Int. 2007;27(12):1187.
   PubMed Web of Science ®Google Scholar
• Bargagli E, Margollicci M, Luddi A, et al. Chitotriosidase activity in patients with interstitial lung diseases. Respir Med. 2007;101(10):2176–2181.
   PubMed Web of Science ®Google Scholar
• Wahlstrom J, Katchar K, Wigzell H, et al. Analysis of intracellular cytokines in CD4+ and CD8+ lung and blood T cells in sarcoidosis. Am J Respir Crit Care Med. 2001;163(1):115–121.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Culver DA, Judson MA. A concise review of pulmonary sarcoidosis. Am J Respir Crit Care Med. 2011;183(5):573–581.
   PubMed Web of Science ®Google Scholar
• Bonecchi R, Bianchi G, Bordignon PP, et al. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J Exp Med. 1998;187(1):129–134.
   PubMed Web of Science ®Google Scholar
• Agostini C, Cassatella M, Zambello R, et al. Involvement of the IP-10 chemokine in sarcoid granulomatous reactions. J Immunol. 1998;161(11):6413–6420.
   PubMed Web of Science ®Google Scholar
• Katchar K, Eklund A, Grunewald J. Expression of Th1 markers by lung accumulated T cells in pulmonary sarcoidosis. J Intern Med. 2003;254(6):564–571.
   PubMed Web of Science ®Google Scholar
• Cox MA, Jenh CH, Gonsiorek W, et al. Human interferon-inducible 10-kDa protein and human interferon-inducible T cell alpha chemoattractant are allotopic ligands for human CXCR3: differential binding to receptor states. Mol Pharmacol. 2001;59(4):707–715.
   PubMed Web of Science ®Google Scholar
• Colvin RA, Campanella GS, Sun J, et al. Intracellular domains of CXCR3 that mediate CXCL9, CXCL10, and CXCL11 function. J Biol Chem. 2004;279(29):30219–30227.
   PubMed Web of Science ®Google Scholar
• Cole KE, Strick CA, Paradis TJ, et al. Interferon-inducible T cell alpha chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3. J Exp Med. 1998;187(12):2009–2021.
   PubMed Web of Science ®Google Scholar
• Miotto D, Christodoulopoulos P, Olivenstein R, et al. Expression of IFN-gamma-inducible protein; monocyte chemotactic proteins 1, 3, and 4; and eotaxin in TH1- and TH2-mediated lung diseases. J Allergy Clin Immunol. 2001;107(4):664–670.
   PubMed Web of Science ®Google Scholar
• Nishioka Y, Manabe K, Kishi J, et al. CXCL9 and 11 in patients with pulmonary sarcoidosis: a role of alveolar macrophages. Clin Exp Immunol. 2007;149(2):317–326.
   PubMed Web of Science ®Google Scholar
• Piotrowski WJ, Mlynarski W, Fendler W, et al. Chemokine receptor CXCR3 ligands in bronchoalveolar lavage fluid: associations with radiological pattern, clinical course, and prognosis in sarcoidosis. Pol Arch Med Wewn. 2014;124(7–8):395–402.
   PubMed Web of Science ®Google Scholar
• Su R, Nguyen ML, Agarwal MR, et al. Interferon-inducible chemokines reflect severity and progression in sarcoidosis. Respir Res. 2013;14:121.
   PubMed Web of Science ®Google Scholar
• Su R, Li MM, Bhakta NR, et al. Longitudinal analysis of sarcoidosis blood transcriptomic signatures and disease outcomes. Eur Respir J. 2014;44(4):985–993.
   PubMed Web of Science ®Google Scholar
• Silverstein E, Friedland J, Ackerman T. Elevation of granulomatous lymph-node and serum lysozyme in sarcoidosis and correlation with angiotensin-converting enzyme. Am J Clin Pathol. 1977;68(2):219–224.
   PubMed Web of Science ®Google Scholar
• Tomita H, Sato S, Matsuda R, et al. Serum lysozyme levels and clinical features of sarcoidosis. Lung. 1999;177(3):161–167.
   PubMed Web of Science ®Google Scholar
• Gronhagen-Riska C, Selroos O. Angiotensin converting enzyme. IV. Changes in serum activity and in lysozyme concentrations as indicators of the course of untreated sarcoidosis. Scand J Respir Dis. 1979;60(6):337–344.
   PubMedGoogle Scholar
• Turton CW, Grundy E, Firth G, et al. Value of measuring serum angiotensin I converting enzyme and serum lysozyme in the management of sarcoidosis. Thorax. 1979;34(1):57–62.
   PubMed Web of Science ®Google Scholar
• Miyoshi S, Hamada H, Kadowaki T, et al. Comparative evaluation of serum markers in pulmonary sarcoidosis. Chest. 2010;137(6):1391–1397.
   PubMed Web of Science ®Google Scholar
• Kohno N, Kyoizumi S, Awaya Y, et al. New serum indicator of interstitial pneumonitis activity. Sialylated carbohydrate antigen KL-6. Chest. 1989;96(1):68–73.
   PubMed Web of Science ®Google Scholar
• Kobayashi J, Kitamura S. Serum KL-6 for the evaluation of active pneumonitis in pulmonary sarcoidosis. Chest. 1996;109(5):1276–1282.
   PubMed Web of Science ®Google Scholar
• Ohnishi H, Yokoyama A, Yasuhara Y, et al. Circulating KL-6 levels in patients with drug induced pneumonitis. Thorax. 2003;58(10):872–875.
   PubMed Web of Science ®Google Scholar
• Ohnishi H, Yokoyama A, Kondo K, et al. Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases. Am J Respir Crit Care Med. 2002;165(3):378–381.
   PubMed Web of Science ®Google Scholar
• Hamada H, Kohno N, Akiyama M, et al. Monitoring of serum KL-6 antigen in a patient with radiation pneumonia. Chest. 1992;101(3):858–860.
   PubMed Web of Science ®Google Scholar
• Janssen R, Sato H, Grutters JC, et al. Study of Clara cell 16, KL-6, and surfactant protein-D in serum as disease markers in pulmonary sarcoidosis. Chest. 2003;124(6):2119–2125.
   PubMed Web of Science ®Google Scholar
• Bell NH, Stern PH, Pantzer E, et al. Evidence that increased circulating 1 alpha, 25-dihydroxyvitamin D is the probable cause for abnormal calcium metabolism in sarcoidosis. J Clin Invest. 1979;64(1):218–225.
   PubMed Web of Science ®Google Scholar
• Adams JS, Sharma OP, Gacad MA, et al. Metabolism of 25-hydroxyvitamin D3 by cultured pulmonary alveolar macrophages in sarcoidosis. J Clin Invest. 1983;72(5):1856–1860.
   PubMed Web of Science ®Google Scholar
• Sharma OP. Renal sarcoidosis and hypercalcemia. Eur Respir J Monogr. 2005;32:220–232.
   Google Scholar
• Burke RR, Rybicki BA, Rao DS. Calcium and vitamin D in sarcoidosis: how to assess and manage. Semin Respir Crit Care Med. 2010;31(4):474–484.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Janovcik J, Ray M, et al. Calcium and vitamin D metabolism in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2013;30(2):113–120.
   PubMed Web of Science ®Google Scholar
• Vucinic V, Skodric-Trifunovic V, Ignjatovic S. How to diagnose and manage difficult problems of calcium metabolism in sarcoidosis: an evidence-based review. Curr Opin Pulm Med. 2011;17(5):297–302.
   PubMed Web of Science ®Google Scholar
• Hamada K, Nagai S, Tsutsumi T, et al. Ionized calcium and 1,25-dihydroxyvitamin D concentration in serum of patients with sarcoidosis. Eur Respir J. 1998;11(5):1015–1020.
   PubMed Web of Science ®Google Scholar
• Basile JN, Liel Y, Shary J, et al. Increased calcium intake does not suppress circulating 1,25-dihydroxyvitamin D in normocalcemic patients with sarcoidosis. J Clin Invest. 1993;91(4):1396–1398.
   PubMed Web of Science ®Google Scholar
• Kavathia D, Buckley JD, Rao D, et al. Elevated 1, 25-dihydroxyvitamin D levels are associated with protracted treatment in sarcoidosis. Respir Med. 2010;104(4):564–570.
   PubMed Web of Science ®Google Scholar
• Kalkanis A, Kalkanis D, Drougas D, et al. Correlation of spleen metabolism assessed by 18F-FDG PET with serum interleukin-2 receptor levels and other biomarkers in patients with untreated sarcoidosis. Nucl Med Commun. 2015;37(3):273–277.
   Web of Science ®Google Scholar
• Fehrenbach H, Zissel G, Goldmann T, et al. Alveolar macrophages are the main source for tumour necrosis factor-alpha in patients with sarcoidosis. Eur Respir J. 2003;21(3):421–428.
   PubMed Web of Science ®Google Scholar
• Ziegenhagen MW, Schrum S, Zissel G, et al. Increased expression of proinflammatory chemokines in bronchoalveolar lavage cells of patients with progressing idiopathic pulmonary fibrosis and sarcoidosis. J Invest Med. 1998;46(5):223–231.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Drent M, Kavuru M, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med. 2006;174(7):795–802.
   PubMed Web of Science ®Google Scholar
• Judson MA, Baughman RP, Costabel U, et al. Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial. Eur Respir J. 2008;31(6):1189–1196.
   PubMed Web of Science ®Google Scholar
• Seitzer U, Swider C, Stuber F, et al. Tumour necrosis factor alpha promoter gene polymorphism in sarcoidosis. Cytokine. 1997;9(10):787–790.
   PubMed Web of Science ®Google Scholar
• Wijnen PA, Nelemans PJ, Verschakelen JA, et al. The role of tumor necrosis factor alpha G-308A polymorphisms in the course of pulmonary sarcoidosis. Tissue Antigens. 2010;75(3):262–268.
   PubMedGoogle Scholar
• Wijnen PA, Cremers JP, Nelemans PJ, et al. Association of the TNF-alpha G-308A polymorphism with TNF-inhibitor response in sarcoidosis. Eur Respir J. 2014;43(6):1730–1739.
   PubMed Web of Science ®Google Scholar
• Chen ES, Song Z, Willett MH, et al. Serum amyloid A regulates granulomatous inflammation in sarcoidosis through toll-like receptor-2. Am J Respir Crit Care Med. 2010;181(4):360–373.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Chen X, Hu Y, et al. Preliminary characterizations of a serum biomarker for sarcoidosis by comparative proteomic approach with tandem-mass spectrometry in ethnic Han Chinese patients. Respir Res. 2013;14:18.
   PubMed Web of Science ®Google Scholar
• Gungor S, Ozseker F, Yalcinsoy M, et al. Conventional markers in determination of activity of sarcoidosis. Int Immunopharmacol. 2015;25(1):174–179.
   PubMed Web of Science ®Google Scholar
• Casanova N, Zhou T, Knox KS, et al. Identifying novel biomarkers in sarcoidosis using genome-based approaches. Clin Chest Med. 2015;36(4):621–630.
   PubMed Web of Science ®Google Scholar
• Isa H, Luthert P, Rose G, et al. Tissue interleukin-17 and interleukin-23 as biomarkers for orbital granulomatosis with polyangiitis. Ophthalmology. 2015;122(10):2140–2142.
   PubMed Web of Science ®Google Scholar
• Ostadkarampour M, Eklund A, Moller D, et al. Higher levels of interleukin IL-17 and antigen-specific IL-17 responses in pulmonary sarcoidosis patients with Lofgren’s syndrome. Clin Exp Immunol. 2014;178(2):342–352.
   PubMed Web of Science ®Google Scholar
• Wu W, Jin M, Wang Y, et al. Overexpression of IL-17RC associated with ocular sarcoidosis. J Transl Med. 2014;12:152.
   PubMed Web of Science ®Google Scholar
• Piotrowski WJ, Kiszalkiewicz J, Pastuszak-Lewandoska D, et al. TGF-beta and SMADs mRNA expression in pulmonary sarcoidosis. Adv Exp Med Biol. 2015;852:59–69.
   PubMed Web of Science ®Google Scholar
• Dubaniewicz A, Typiak M, Wybieralska M, et al. Changed phagocytic activity and pattern of Fcgamma and complement receptors on blood monocytes in sarcoidosis. Hum Immunol. 2012;73(8):788–794.
   PubMed Web of Science ®Google Scholar
• Maertzdorf J, Weiner J 3rd, Mollenkopf HJ, et al. Common patterns and disease-related signatures in tuberculosis and sarcoidosis. Proc Natl Acad Sci U S A. 2012;109(20):7853–7858.
   PubMed Web of Science ®Google Scholar
• Rivera NV, Ronninger M, Shchetynsky K, et al. High-density genetic mapping identifies new susceptibility variants in sarcoidosis phenotypes and shows genomic-driven phenotypic differences. Am J Respir Crit Care Med. 2016;193:1008–1022.
   PubMed Web of Science ®Google Scholar
• Fischer A, Ellinghaus D, Nutsua M, et al. Identification of immune-relevant factors conferring sarcoidosis genetic risk. Am J Respir Crit Care Med. 2015;192(6):727–736.
   PubMed Web of Science ®Google Scholar
• Typiak M, Rebala K, Dudziak M, et al. Polymorphism of FCGR2A, FCGR2C, and FCGR3B genes in the pathogenesis of sarcoidosis. Adv Exp Med Biol. 2016;905:57–68.
   PubMedGoogle Scholar
• Typiak MJ, Rebala K, Dudziak M, et al. Polymorphism of FCGR3A gene in sarcoidosis. Hum Immunol. 2014;75(4):283–288.
   PubMed Web of Science ®Google Scholar
• Hofmann S, Franke A, Fischer A, et al. Genome-wide association study identifies ANXA11 as a new susceptibility locus for sarcoidosis. Nat Genet. 2008;40(9):1103–1106.
   PubMed Web of Science ®Google Scholar
• Rossman MD, Thompson B, Frederick M, et al. HLA-DRB1*1101: a significant risk factor for sarcoidosis in blacks and whites. Am J Hum Genet. 2003;73(4):720–735.
   PubMed Web of Science ®Google Scholar
• Adrianto I, Lin CP, Hale JJ, et al. Genome-wide association study of African and European Americans implicates multiple shared and ethnic specific loci in sarcoidosis susceptibility. PLoS One. 2012;7(8):e43907.
   PubMed Web of Science ®Google Scholar
• Moller DR, Koth LL, Maier LA, et al. Rationale and design of the Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) study. Sarcoidosis protocol. Ann Am Thorac Soc. 2015;12(10):1561–1571.
   PubMed Web of Science ®Google Scholar
• Ma Y, Gal A, Koss MN. The pathology of pulmonary sarcoidosis: update. Semin Diagn Pathol. 2007;24(3):150–161.
   PubMed Web of Science ®Google Scholar
• Nakatsu M, Hatabu H, Morikawa K, et al. Large coalescent parenchymal nodules in pulmonary sarcoidosis: “sarcoid galaxy” sign. Ajr. 2002;178(6):1389–1393.
   PubMed Web of Science ®Google Scholar
• Warshauer DM, Dumbleton SA, Molina PL, et al. Abdominal CT findings in sarcoidosis: radiologic and clinical correlation. Radiology. 1994;192(1):93–98.
   PubMed Web of Science ®Google Scholar
• Warshauer DM, Molina PL, Hamman SM, et al. Nodular sarcoidosis of the liver and spleen: analysis of 32 cases. Radiology. 1995;195(3):757–762.
   PubMed Web of Science ®Google Scholar
• Farman J, Ramirez G, Brunetti J, et al. Abdominal manifestations of sarcoidosis. CT appearances. Clin Imaging. 1995;19(1):30–33.
   PubMed Web of Science ®Google Scholar
• Tsan MF, Chen WY, Scheffel U, et al. Studies on gallium accumulation in inflammatory lesions: I. Gallium uptake by human polymorphonuclear leukocytes. J Nucl Med. 1978;19(1):36–43.
   PubMed Web of Science ®Google Scholar
• Mana J. Magnetic resonance imaging and nuclear imaging in sarcoidosis. Curr Opin Pulm Med. 2002;8(5):457–463.
   PubMed Web of Science ®Google Scholar
• Alberts C, Van Der Schoot JB, Van Daatselaar JJ, et al. 67Ga scintigraphy, serum lysozyme and angiotensin-converting enzyme in pulmonary sarcoidosis. Eur J Respir Dis. 1983;64(1):38–46.
   PubMedGoogle Scholar
• Duffy GJ, Thirumurthi K, Casey M, et al. Semi-quantitative gallium-67 lung scanning as a measure of the intensity of alveolitis in pulmonary sarcoidosis. Eur J Nucl Med. 1986;12(4):187–191.
   PubMedGoogle Scholar
• Fajman WA, Greenwald LV, Staton G, et al. Assessing the activity of sarcoidosis: quantitative 67Ga-citrate imaging. Ajr. 1984;142(4):683–688.
   PubMed Web of Science ®Google Scholar
• Nunes H, Brillet PY, Valeyre D, et al. Imaging in sarcoidosis. Semin Respir Crit Care Med. 2007;28(1):102–120.
   PubMed Web of Science ®Google Scholar
• Sulavik SB, Palestro CJ, Spencer RP, et al. Extrapulmonary sites of radiogallium accumulation in sarcoidosis. Clin Nucl Med. 1990;15(12):876–878.
   PubMed Web of Science ®Google Scholar
• Sulavik SB, Spencer RP, Palestro CJ, et al. Specificity and sensitivity of distinctive chest radiographic and/or 67Ga images in the noninvasive diagnosis of sarcoidosis. Chest. 1993;103(2):403–409.
   PubMed Web of Science ®Google Scholar
• Israel HL, Albertine KH, Park CH, et al. Whole-body gallium 67 scans. Role in diagnosis of sarcoidosis. Am Rev Respir Dis. 1991;144(5):1182–1186.
   PubMed Web of Science ®Google Scholar
• Lewis PJ, Salama A. Uptake of fluorine-18-fluorodeoxyglucose in sarcoidosis. J Nucl Med. 1994;35(10):1647–1649.
   PubMed Web of Science ®Google Scholar
• Xiu Y, Yu JQ, Cheng E, et al. Sarcoidosis demonstrated by FDG PET imaging with negative findings on gallium scintigraphy. Clin Nucl Med. 2005;30(3):193–195.
   PubMed Web of Science ®Google Scholar
• Teirstein AS, Machac J, Almeida O, et al. Results of 188 whole-body fluorodeoxyglucose positron emission tomography scans in 137 patients with sarcoidosis. Chest. 2007;132(6):1949–1953.
   PubMed Web of Science ®Google Scholar
• Cremers JP, Van Kroonenburgh MJ, Mostard RL, et al. Extent of disease activity assessed by 18F-FDG PET/CT in a Dutch sarcoidosis population. Sarcoidosis Vasc Diffuse Lung Dis. 2014;31(1):37–45.
   PubMed Web of Science ®Google Scholar
• Vansteenkiste JF, Stroobants SG, Dupont PJ, et al. Mediastinal lymph node staging with FDG-PET scan in patients with potentially operable non-small cell lung cancer: a prospective analysis of 50 cases. 1997. Chest. 2009;136(5 Suppl):e30.
   Google Scholar
• Dewan NA, Shehan CJ, Reeb SD, et al. Likelihood of malignancy in a solitary pulmonary nodule: comparison of Bayesian analysis and results of FDG-PET scan. Chest. 1997;112(2):416–422.
   PubMed Web of Science ®Google Scholar
• Maturu VN, Agarwal R, Aggarwal AN, et al. Dual-time point whole-body 18F-fluorodeoxyglucose PET/CT imaging in undiagnosed mediastinal lymphadenopathy: a prospective study of 117 patients with sarcoidosis and TB. Chest. 2014;146(6):e216–220.
   Google Scholar
• Kaira K, Oriuchi N, Otani Y, et al. Diagnostic usefulness of fluorine-18-alpha-methyltyrosine positron emission tomography in combination with 18F-fluorodeoxyglucose in sarcoidosis patients. Chest. 2007;131(4):1019–1027.
   PubMed Web of Science ®Google Scholar
• Muller NL, Mayo JR, Zwirewich CV. Value of MR imaging in the evaluation of chronic infiltrative lung diseases: comparison with CT. Ajr. 1992;158(6):1205–1209.
   PubMed Web of Science ®Google Scholar
• Scadding JG. Prognosis of intrathoracic sarcoidosis in England. A review of 136 cases after five years’ observation. Br Med J. 1961;2(5261):1165–1172.
   PubMed Web of Science ®Google Scholar
• Keijsers RG, Veltkamp M, Grutters JC. Chest imaging. Clin Chest Med. 2015;36(4):603–619.
   PubMed Web of Science ®Google Scholar
• Judson MA. The clinical features of sarcoidosis: a comprehensive review. Clin Rev Allergy Immunol. 2015;49(1):63–78.
   PubMed Web of Science ®Google Scholar
• Handa T, Nagai S, Miki S, et al. Incidence of pulmonary hypertension and its clinical relevance in patients with sarcoidosis. Chest. 2006;129(5):1246–1252.
   PubMed Web of Science ®Google Scholar
• Pena TA, Soubani AO, Samavati L. Aspergillus lung disease in patients with sarcoidosis: a case series and review of the literature. Lung. 2011;189(2):167–172.
   PubMed Web of Science ®Google Scholar
• Rafferty P, Biggs BA, Crompton GK, et al. What happens to patients with pulmonary aspergilloma? Analysis of 23 cases. Thorax. 1983;38(8):579–583.
   PubMed Web of Science ®Google Scholar
• Reich JM, Brouns MC, O’Connor EA, et al. Mediastinoscopy in patients with presumptive stage I sarcoidosis: a risk/benefit, cost/benefit analysis. Chest. 1998;113(1):147–153.
   PubMed Web of Science ®Google Scholar
• Winterbauer RH, Belic N, Moores KD. Clinical interpretation of bilateral hilar adenopathy. Ann Intern Med. 1973;78(1):65–71.
   PubMed Web of Science ®Google Scholar
• Judson MA. The diagnosis of sarcoidosis. Clin Chest Med. 2008;29(3):415–427, viii.
   PubMed Web of Science ®Google Scholar
• Lynch JP 3rd, Ma YL, Koss MN, et al. Pulmonary sarcoidosis. Semin Respir Crit Care Med. 2007;28(1):53–74.
   PubMed Web of Science ®Google Scholar
• Nishimura K, Itoh H, Kitaichi M, et al. Pulmonary sarcoidosis: correlation of CT and histopathologic findings. Radiology. 1993;189(1):105–109.
   PubMed Web of Science ®Google Scholar
• Brauner MW, Lenoir S, Grenier P, et al. Pulmonary sarcoidosis: CT assessment of lesion reversibility. Radiology. 1992;182(2):349–354.
   PubMed Web of Science ®Google Scholar
• Mostard RL, Voo S, Van Kroonenburgh MJ, et al. Inflammatory activity assessment by F18 FDG-PET/CT in persistent symptomatic sarcoidosis. Respir Med. 2011;105(12):1917–1924.
   PubMed Web of Science ®Google Scholar
• Keijsers RG, Verzijlbergen EJ, Van Den Bosch JM, et al. 18F-FDG PET as a predictor of pulmonary function in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2011;28(2):123–129.
   PubMed Web of Science ®Google Scholar
• Vorselaars AD, Crommelin HA, Deneer VH, et al. Effectiveness of infliximab in refractory FDG PET-positive sarcoidosis. Eur Respir J. 2015;46(1):175–185.
   PubMed Web of Science ®Google Scholar
• Keijsers RG, Grutters JC, Van Velzen-Blad H, et al. (18)F-FDG PET patterns and BAL cell profiles in pulmonary sarcoidosis. Eur J Nucl Med Mol Imaging. 2010;37(6):1181–1188.
   PubMed Web of Science ®Google Scholar
• Ambrosini V, Zompatori M, Fasano L, et al. (18)F-FDG PET/CT for the assessment of disease extension and activity in patients with sarcoidosis: results of a preliminary prospective study. Clin Nucl Med. 2013;38(4):e171–177.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Drent M, Culver DA, et al. Endpoints for clinical trials of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2012;29(2):90–98.
   PubMed Web of Science ®Google Scholar
• Sansores RH, Ramirez-Venegas A, Perez-Padilla R, et al. Correlation between pulmonary fibrosis and the lung pressure-volume curve. Lung. 1996;174(5):315–323.
   PubMed Web of Science ®Google Scholar
• Polychronopoulos VS, Prakash UB. Airway involvement in sarcoidosis. Chest. 2009;136(5):1371–1380.
   PubMed Web of Science ®Google Scholar
• Shorr AF, Torrington KG, Hnatiuk OW. Endobronchial biopsy for sarcoidosis: a prospective study. Chest. 2001;120(1):109–114.
   PubMed Web of Science ®Google Scholar
• Shorr AF, Torrington KG, Hnatiuk OW. Endobronchial involvement and airway hyperreactivity in patients with sarcoidosis. Chest. 2001;120(3):881–886.
   PubMed Web of Science ®Google Scholar
• Miller A, Teirstein AS, Jackler I, et al. Airway function in chronic pulmonary sarcoidosis with fibrosis. Am Rev Respir Dis. 1974;109(2):179–189.
   PubMed Web of Science ®Google Scholar
• Marcias S, Ledda MA, Perra R, et al. Aspecific bronchial hyperreactivity in pulmonary sarcoidosis. Sarcoidosis. 1994;11(2):118–122.
   PubMedGoogle Scholar
• Bechtel JJ, Starr T 3rd, Dantzker DR, et al. Airway hyperreactivity in patients with sarcoidosis. Am Rev Respir Dis. 1981;124(6):759–761.
   PubMed Web of Science ®Google Scholar
• Judson MA, Strange C. Bullous sarcoidosis: a report of three cases. Chest. 1998;114(5):1474–1478.
   PubMed Web of Science ®Google Scholar
• Chambellan A, Turbie P, Nunes H, et al. Endoluminal stenosis of proximal bronchi in sarcoidosis: bronchoscopy, function, and evolution. Chest. 2005;127(2):472–481.
   PubMed Web of Science ®Google Scholar
• Hunninghake GW, Gilbert S, Pueringer R, et al. Outcome of the treatment for sarcoidosis. Am J Respir Crit Care Med. 1994;149(4 Pt 1):893–898.
   PubMed Web of Science ®Google Scholar
• Judson MA, Boan AD, Lackland DT. The clinical course of sarcoidosis: presentation, diagnosis, and treatment in a large white and black cohort in the United States. Sarcoidosis Vasc Diffuse Lung Dis. 2012;29(2):119–127.
   PubMed Web of Science ®Google Scholar
• Cox CE, Donohue JF, Brown CD, et al. The Sarcoidosis Health Questionnaire: a new measure of health-related quality of life. Am J Respir Crit Care Med. 2003;168(3):323–329.
   PubMed Web of Science ®Google Scholar
• Cox CE, Donohue JF, Brown CD, et al. Health-related quality of life of persons with sarcoidosis. Chest. 2004;125(3):997–1004.
   PubMed Web of Science ®Google Scholar
• Yeager H, Rossman MD, Baughman RP, et al. Pulmonary and psychosocial findings at enrollment in the ACCESS study. Sarcoidosis Vasc Diffuse Lung Dis. 2005;22(2):147–153.
   PubMed Web of Science ®Google Scholar
• Lopes AJ, De Menezes SL, Dias CM, et al. Comparison between cardiopulmonary exercise testing parameters and computed tomography findings in patients with thoracic sarcoidosis. Lung. 2011;189(5):425–431.
   PubMed Web of Science ®Google Scholar
• Drent M, Marcellis R, Lenssen A, et al. Association between physical functions and quality of life in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2014;31(2):117–128.
   PubMed Web of Science ®Google Scholar
• Punjabi NM, Shade D, Patel AM, et al. Measurement variability in single-breath diffusing capacity of the lung. Chest. 2003;123(4):1082–1089.
   PubMed Web of Science ®Google Scholar
• Bourbonnais JM, Samavati L. Clinical predictors of pulmonary hypertension in sarcoidosis. Eur Respir J. 2008;32(2):296–302.
   PubMed Web of Science ®Google Scholar
• NIH conference. Pulmonary sarcoidosis: a disease characterized and perpetuated by activated lung T-lymphocytes. Ann Intern Med. 1981;94(1):73–94.
   PubMed Web of Science ®Google Scholar
• Costabel U, Guzman J, Albera C, et al. Bronchoalveolar lavage in sarcoidosis. In: Baughman RP, editor. Lung biology in health and disease; sarcoidosis. Vol. 210. New York: Informa; 2006. p. 399–414.
   Google Scholar
• Nagai S, Izumi T. Bronchoalveolar lavage. Still useful in diagnosing sarcoidosis? Clin Chest Med. 1997;18(4):787–797.
   PubMed Web of Science ®Google Scholar
• Winterbauer RH, Lammert J, Selland M, et al. Bronchoalveolar lavage cell populations in the diagnosis of sarcoidosis. Chest. 1993;104(2):352–361.
   PubMed Web of Science ®Google Scholar
• Costabel U, Bross KJ, Matthys H. Pulmonary sarcoidosis: assessment of disease activity by lung lymphocyte subpopulations. Klin Wochenschr. 1983;61(7):349–356.
   PubMedGoogle Scholar
• Milman N, Kristensen MS, Bentsen K, et al. Hyaluronan and procollagen type III aminoterminal peptide in serum and bronchoalveolar lavage fluid in patients with pulmonary sarcoidosis. Sarcoidosis. 1995;12(1):38–41.
   PubMedGoogle Scholar
• O’Connor C, Odlum C, Van Breda A, et al. Collagenase and fibronectin in bronchoalveolar lavage fluid in patients with sarcoidosis. Thorax. 1988;43(5):393–400.
   PubMed Web of Science ®Google Scholar
• Bjermer L, Eklund A, Blaschke E. Bronchoalveolar lavage fibronectin in patients with sarcoidosis: correlation to hyaluronan and disease activity. Eur Respir J. 1991;4(8):965–971.
   PubMed Web of Science ®Google Scholar
• Bjermer L, Rosenhall L, Angstrom T, et al. Predictive value of bronchoalveolar lavage cell analysis in sarcoidosis. Thorax. 1988;43(4):284–288.
   PubMed Web of Science ®Google Scholar
• Costabel U, Bross KJ, Guzman J, et al. Predictive value of bronchoalveolar T cell subsets for the course of pulmonary sarcoidosis. Ann N Y Acad Sci. 1986;465:418–426.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Shipley R, Eisentrout CE. Predictive value of gallium scan, angiotensin-converting enzyme level, and bronchoalveolar lavage in two-year follow-up of pulmonary sarcoidosis. Lung. 1987;165(6):371–377.
   PubMed Web of Science ®Google Scholar
• Laviolette M, La Forge J, Tennina S, et al. Prognostic value of bronchoalveolar lavage lymphocyte count in recently diagnosed pulmonary sarcoidosis. Chest. 1991;100(2):380–384.
   PubMed Web of Science ®Google Scholar
• Ward K, O’Connor C, Odlum C, et al. Prognostic value of bronchoalveolar lavage in sarcoidosis: the critical influence of disease presentation. Thorax. 1989;44(1):6–12.
   PubMed Web of Science ®Google Scholar
• Drent M, Jacobs JA, De Vries J, et al. Does the cellular bronchoalveolar lavage fluid profile reflect the severity of sarcoidosis? Eur Respir J. 1999;13(6):1338–1344.
   PubMed Web of Science ®Google Scholar
• Lin YH, Haslam PL, Turner-Warwick M. Chronic pulmonary sarcoidosis: relationship between lung lavage cell counts, chest radiograph, and results of standard lung function tests. Thorax. 1985;40(7):501–507.
   PubMed Web of Science ®Google Scholar
• Ziegenhagen MW, Rothe ME, Zissel G, et al. Exaggerated TNFalpha release of alveolar macrophages in corticosteroid resistant sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2002;19(3):185–190.
   PubMed Web of Science ®Google Scholar
• Judson MA, Baughman RP, Costabel U, et al. The potential additional benefit of infliximab in patients with chronic pulmonary sarcoidosis already receiving corticosteroids: a retrospective analysis from a randomized clinical trial. Respir Med. 2014;108(1):189–194.
   PubMed Web of Science ®Google Scholar
• Silverman KJ, Hutchins GM, Bulkley BH. Cardiac sarcoid: a clinicopathological study of 84 unselected patients with systemic sarcoidosis. Circulation. 1978;58:1204–1211.
   PubMed Web of Science ®Google Scholar
• Iwai K, Takemura T, Kitaichi M, et al. Pathological studies on sarcoidosis autopsy. II. Early change, mode of progression and death pattern. Acta Pathol Jpn. 1993;43(7–8):377–385.
   PubMedGoogle Scholar
• Iwai K, Sekiguti M, Hosoda Y, et al. Racial difference in cardiac sarcoidosis incidence observed at autopsy. Sarcoidosis. 1994;11(1):26–31.
   PubMedGoogle Scholar
• Hamzeh N, Steckman DA, Sauer WH, et al. Pathophysiology and clinical management of cardiac sarcoidosis. Nat Rev Cardiol. 2015;12(5):278–288.
   PubMed Web of Science ®Google Scholar
• Birnie DH, Sauer WH, Bogun F, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm. 2014;11(7):1305–1324.
   PubMed Web of Science ®Google Scholar
• Mehta D, Lubitz SA, Frankel Z, et al. Cardiac involvement in patients with sarcoidosis: diagnostic and prognostic value of outpatient testing. Chest. 2008;133(6):1426–1435.
   PubMed Web of Science ®Google Scholar
• Rubinstein I, Fisman EZ, Rosenblum Y, et al. Left-ventricular exercise echocardiographic abnormalities in patients with sarcoidosis without ischemic heart disease. Isr J Med Sci. 1986;22(12):865–872.
   PubMedGoogle Scholar
• Kul S, Guvenc TS, Uyarel H. Speckle tracking echocardiography in cardiac sarcoidosis. Int J Cardiol. 2014;176(3):1329–1330.
   PubMed Web of Science ®Google Scholar
• Kim JS, Judson MA, Donnino R, et al. Cardiac sarcoidosis. Am Heart J. 2009;157(1):9–21.
   PubMed Web of Science ®Google Scholar
• Hamzeh NY, Wamboldt FS, Weinberger HD. Management of cardiac sarcoidosis in the United States: a Delphi study. Chest. 2012;141(1):154–162.
   PubMed Web of Science ®Google Scholar
• Ardehali H, Howard DL, Hariri A, et al. A positive endomyocardial biopsy result for sarcoid is associated with poor prognosis in patients with initially unexplained cardiomyopathy. Am Heart J. 2005;150(3):459–463.
   PubMed Web of Science ®Google Scholar
• Tadamura E, Yamamuro M, Kubo S, et al. Effectiveness of delayed enhanced MRI for identification of cardiac sarcoidosis: comparison with radionuclide imaging. Ajr. 2005;185(1):110–115.
   PubMed Web of Science ®Google Scholar
• Judson MA, Baughman RP, Teirstein AS, et al. Defining organ involvement in sarcoidosis: the ACCESS proposed instrument. ACCESS Research Group. A case control etiologic study of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 1999;16(1):75–86.
   PubMed Web of Science ®Google Scholar
• Judson MA, Costabel U, Drent M, et al. The WASOG sarcoidosis organ assessment instrument: an update of a previous clinical tool. Sarcoidosis Vasc Diffuse Lung Dis. 2014;31(1):19–27.
   PubMed Web of Science ®Google Scholar
• Hiraga H, Yuwai K, Hiroe M. Guideline for diagnosis of cardiac sarcoidosis: study report on diffuse pulmonary diseases from the Japanese Ministry of Health and Welfare [Japanese]. Tokyo: Japanese Ministry of Health and Welfare; 1993. p. 23–24.
   Google Scholar
• Ichinose A, Otani H, Oikawa M, et al. MRI of cardiac sarcoidosis: basal and subepicardial localization of myocardial lesions and their effect on left ventricular function. Ajr. 2008;191(3):862–869.
   PubMed Web of Science ®Google Scholar
• Ordovas KG, Higgins CB. Delayed contrast enhancement on MR images of myocardium: past, present, future. Radiology. 2011;261(2):358–374.
   PubMed Web of Science ®Google Scholar
• Vignaux O, Dhote R, Duboc D, et al. Clinical significance of myocardial magnetic resonance abnormalities in patients with sarcoidosis: a 1-year follow-up study. Chest. 2002;122(6):1895–1901.
   PubMed Web of Science ®Google Scholar
• Crouser ED, Ono C, Tran T, et al. Improved detection of cardiac sarcoidosis using magnetic resonance with myocardial T2 mapping. Am J Respir Crit Care Med. 2014;189(1):109–112.
   PubMed Web of Science ®Google Scholar
• Smedema JP, Snoep G, Van Kroonenburgh MP, et al. Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol. 2005;45(10):1683–1690.
   PubMed Web of Science ®Google Scholar
• Yoshida A, Ishibashi-Ueda H, Yamada N, et al. Direct comparison of the diagnostic capability of cardiac magnetic resonance and endomyocardial biopsy in patients with heart failure. Eur J Heart Fail. 2013;15(2):166–175.
   PubMed Web of Science ®Google Scholar
• Youssef G, Leung E, Mylonas I, et al. The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: a systematic review and metaanalysis including the Ontario experience. J Nucl Med. 2012;53(2):241–248.
   PubMed Web of Science ®Google Scholar
• Langah R, Spicer K, Gebregziabher M, et al. Effectiveness of prolonged fasting 18f-FDG PET-CT in the detection of cardiac sarcoidosis. J Nucl Cardiol. 2009;16(5):801–810.
   PubMed Web of Science ®Google Scholar
• De Groot M, Meeuwis AP, Kok PJ, et al. Influence of blood glucose level, age and fasting period on non-pathological FDG uptake in heart and gut. Eur J Nucl Med Mol Imaging. 2005;32(1):98–101.
   PubMed Web of Science ®Google Scholar
• Blankstein R, Osborne M, Naya M, et al. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. J Am Coll Cardiol. 2014;63(4):329–336.
   PubMed Web of Science ®Google Scholar
• Tung R, Bauer B, Schelbert H, et al. Incidence of abnormal positron emission tomography in patients with unexplained cardiomyopathy and ventricular arrhythmias: the potential role of occult inflammation in arrhythmogenesis. Heart Rhythm. 2015;12(12):2488–2498.
   PubMed Web of Science ®Google Scholar
• Forman MB, Sandler MP, Sacks GA, et al. Radionuclide imaging in myocardial sarcoidosis. Demonstration of myocardial uptake of technetium pyrophosphate99m and gallium. Chest. 1983;83(3):578–580.
   PubMed Web of Science ®Google Scholar
• Umetani K, Ishihara T, Yamamoto K, et al. Successfully treated complete atrioventricular block with corticosteroid in a patient with cardiac sarcoidosis: usefulness of gallium-67 and thallium-201 scintigraphy. Intern Med. 2000;39(3):245–248.
   PubMed Web of Science ®Google Scholar
• Take Y, Morita H. Fragmented QRS: what is the meaning? Indian Pacing Electrophysiol J. 2012;12(5):213–225.
   PubMedGoogle Scholar
• Schuller JL, Olson MD, Zipse MM, et al. Electrocardiographic characteristics in patients with pulmonary sarcoidosis indicating cardiac involvement. J Cardiovasc Electrophysiol. 2011;22(11):1243–1248.
   PubMed Web of Science ®Google Scholar
• Schuller JL, Lowery CM, Zipse M, et al. Diagnostic utility of signal-averaged electrocardiography for detection of cardiac sarcoidosis. Ann Noninvasive Electrocardiol. 2011;16(1):70–76.
   PubMed Web of Science ®Google Scholar
• Matsumoto S, Hirayama Y, Saitoh H, et al. Noninvasive diagnosis of cardiac sarcoidosis using microvolt T-wave alternans. Int Heart J. 2009;50(6):731–739.
   PubMed Web of Science ®Google Scholar
• Matoh F, Satoh H, Shiraki K, et al. The usefulness of delayed enhancement magnetic resonance imaging for diagnosis and evaluation of cardiac function in patients with cardiac sarcoidosis. J Cardiol. 2008;51(3):179–188.
   PubMed Web of Science ®Google Scholar
• Watanabe E, Kimura F, Nakajima T, et al. Late gadolinium enhancement in cardiac sarcoidosis: characteristic magnetic resonance findings and relationship with left ventricular function. J Thorac Imaging. 2013;28(1):60–66.
   PubMed Web of Science ®Google Scholar
• Ise T, Hasegawa T, Morita Y, et al. Extensive late gadolinium enhancement on cardiovascular magnetic resonance predicts adverse outcomes and lack of improvement in LV function after steroid therapy in cardiac sarcoidosis. Heart. 2014;100(15):1165–1172.
   PubMed Web of Science ®Google Scholar
• Greulich S, Deluigi CC, Gloekler S, et al. CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis. JACC Cardiovasc Imaging. 2013;6(4):501–511.
   PubMed Web of Science ®Google Scholar
• Crawford T, Mueller G, Sarsam S, et al. Magnetic resonance imaging for identifying patients with cardiac sarcoidosis and preserved or mildly reduced left ventricular function at risk of ventricular arrhythmias. Circ Arrhythm Electrophysiol. 2014;7(6):1109–1115.
   PubMed Web of Science ®Google Scholar
• Yazaki Y, Isobe M, Hiroe M, et al. Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol. 2001;88(9):1006–1010.
   PubMed Web of Science ®Google Scholar
• Miyazawa K, Yoshikawa T, Takamisawa I, et al. Presence of ventricular aneurysm predicts poor clinical outcomes in patients with cardiac sarcoidosis. Int J Cardiol. 2014;177(2):720–722.
   PubMed Web of Science ®Google Scholar
• Kandolin R, Lehtonen J, Airaksinen J, et al. Cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25 years in a nationwide study. Circulation. 2015;131(7):624–632.
   PubMed Web of Science ®Google Scholar
• Nozaki K, Scott TF, Sohn M, et al. Isolated neurosarcoidosis: case series in 2 sarcoidosis centers. Neurologist. 2012;18(6):373–377.
   PubMed Web of Science ®Google Scholar
• Zajicek JP, Scolding NJ, Foster O, et al. Central nervous system sarcoidosis–diagnosis and management. Qjm. 1999;92(2):103–117.
   PubMed Web of Science ®Google Scholar
• Agbogu BN, Stern BJ, Sewell C, et al. Therapeutic considerations in patients with refractory neurosarcoidosis. Arch Neurol. 1995;52(9):875–879.
   PubMedGoogle Scholar
• Westhout FD, Linskey ME. Obstructive hydrocephalus and progressive psychosis: rare presentations of neurosarcoidosis. Surg Neurol. 2008;69(3):288–292; discussion 292.
   Google Scholar
• Pickuth D, Heywang-Kobrunner SH. Neurosarcoidosis: evaluation with MRI. J Neuroradiol. 2000;27(3):185–188.
   PubMed Web of Science ®Google Scholar
• Spencer TS, Campellone JV, Maldonado I, et al. Clinical and magnetic resonance imaging manifestations of neurosarcoidosis. Semin Arthritis Rheum. 2005;34(4):649–661.
   PubMed Web of Science ®Google Scholar
• Dumas JL, Valeyre D, Chapelon-Abric C, et al. Central nervous system sarcoidosis: follow-up at MR imaging during steroid therapy. Radiology. 2000;214(2):411–420.
   PubMed Web of Science ®Google Scholar
• Smith JK, Matheus MG, Castillo M. Imaging manifestations of neurosarcoidosis. Ajr. 2004;182(2):289–295.
   PubMed Web of Science ®Google Scholar
• Shah R, Roberson GH, Cure JK. Correlation of MR imaging findings and clinical manifestations in neurosarcoidosis. Ajnr. 2009;30(5):953–961.
   PubMed Web of Science ®Google Scholar
• Sherman JL, Stern BJ. Sarcoidosis of the CNS: comparison of unenhanced and enhanced MR images. Ajr. 1990;155(6):1293–1301.
   PubMed Web of Science ®Google Scholar
• Huang JF, Aksamit AJ, Staff NPMRI. PET imaging discordance in neurosarcoidosis. Neurology. 2012;79(10):1070.
   PubMed Web of Science ®Google Scholar
• Dubey N, Miletich RS, Wasay M, et al. Role of fluorodeoxyglucose positron emission tomography in the diagnosis of neurosarcoidosis. J Neurol Sci. 2002;205(1):77–81.
   PubMed Web of Science ®Google Scholar
• Kim SK, Im HJ, Kim W, et al. F-18 fluorodeoxyglucose and F-18 fluorothymidine positron emission tomography/computed tomography imaging in a case of neurosarcoidosis. Clin Nucl Med. 2010;35(2):67–70.
   PubMed Web of Science ®Google Scholar
• Sakushima K, Yabe I, Shiga T, et al. FDG-PET SUV can distinguish between spinal sarcoidosis and myelopathy with canal stenosis. J Neurol. 2011;258(2):227–230.
   PubMed Web of Science ®Google Scholar
• Nozaki K, Judson MA. Neurosarcoidosis: clinical manifestations, diagnosis and treatment. Presse Med. 2012;41(6 Pt 2):e331–348.
   PubMedGoogle Scholar
• Stern BJ, Krumholz A, Johns C, et al. Sarcoidosis and its neurological manifestations. Arch Neurol. 1985;42(9):909–917.
   PubMedGoogle Scholar
• Pawate S, Moses H, Sriram S. Presentations and outcomes of neurosarcoidosis: a study of 54 cases. Qjm. 2009;102(7):449–460.
   PubMed Web of Science ®Google Scholar
• Newman LS, Orton R, Kreiss K. Serum angiotensin converting enzyme activity in chronic beryllium disease. Am Rev Respir Dis 1992;146(1):39–42.
   PubMed Web of Science ®Google Scholar
• Huuskonen MS, Jarvisalo J, Koskinen H, et al. Serum angiotensin-converting enzyme and lysosomal enzymes in tobacco workers. Chest. 1986;89(2):224–228.
   PubMed Web of Science ®Google Scholar
• Maddrey WC. Sarcoidosis and primary biliary cirrhosis. Associated disorders? N Engl J Med. 1983;308(10):588–590.
   PubMed Web of Science ®Google Scholar
• Lieberman J, Sastre A. Serum angiotensin-converting enzyme: elevations in diabetes mellitus. Ann Intern Med. 1980;93(6):825–826.
   PubMed Web of Science ®Google Scholar
• Yotsumoto H, Imai Y, Kuzuya N, Uchimura H, Matsuzaki F. Increased levels of serum angiotensin-converting enzyme activity in hyperthyroidism. Ann Intern Med. 1982;96(3):326–328.
   PubMed Web of Science ®Google Scholar
• Silverstein E, Brunswick J, Rao TK, Friedland J. Increased serum angiotensin-converting enzyme in chronic renal disease. Nephron. 1984;37(3):206–210.
   PubMed Web of Science ®Google Scholar
• Ryder KW, Epinette WW, Jay SJ, Ransburg RC, Glick MR. Serum angiotensin converting enzyme activity in patients with psoriasis. Clin Chimica Acta; Int J Clin Chem. 1985;153(2):143–146.
   PubMed Web of Science ®Google Scholar
• Ena P, Madeddu P, Rappelli A, Cerimele D. Serum angiotensin-converting enzyme activity in psoriasis. Dermatologica. 1987;174(3):110–113.
   PubMedGoogle Scholar
• Matsuki K, Sakata T. Angiotensin-converting enzyme in diseases of the liver. Am J Med. 1982;73(4):549–551.
   PubMed Web of Science ®Google Scholar
• Beyazit Y, Purnak T, Suvak B, et al. Increased ACE in extrahepatic cholangiocarcinoma as a clue for activated RAS in biliary neoplasms. Clin Res hepatol gastroenterol. 2011;35(10):644–649.
   PubMed Web of Science ®Google Scholar
• Luisetti M, Martinetti M, Cuccia M, et al. Familial elevation of serum angiotensin converting enzyme activity. Eur Respir J. 1990;3(4):441–446.
   PubMed Web of Science ®Google Scholar